Nicola S. Vos, MD

Original Contribution

Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes

10/15/2018

Mark S. Patterson , MBBS, PhD, MD, MRCP;

René J. Van Der Schaaf , MD, PhD;

Jean-Paul R. Herrman , MD, PhD;

Ton Slagboom , MD;

Maarten A. Vink , MD, PhD;

Moniek Maarse , MD;

Rob Adams , MSc;

Robbert J. de Winter , MD, PhD;

Nicola S. Vos , MD;

Giovanni Amoroso , MD, PhD;

Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...

Pretreatment with P2Y12...

10/15/2018

Journal of Invasive Cardiology

Original Contribution

One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study

07/25/2017

Alexander JJ. IJsselmuiden , MD, PhD;

Rainer Wessely , MD, PhD;

Thomas Dengler , MD;

Johanne Silvain , MD, PhD;

Joanna J. Wykrzykowska , MD, PhD;

Gilles Montalescot , MD, PhD;

Jan G.P. Tijssen , PhD;

Rene Spaargaren , MD;

Giovanni Amoroso , MD, PhD;

Karel T. Koch , MD, PhD;

Robbert J. de Winter , MD, PhD;

Alessio La Manna , MD;

Robert Jan van Geuns , MD, PhD;

Maik J. Grundeken , MD;

Huangling Lu , MD;

Nicola S. Vos , MD;

We investigated outcomes in STEMI patients after Stentys treatment for bifurcation culprit lesions.

We investigated outcomes in...

07/25/2017

Journal of Invasive Cardiology

Original Contribution

Two-Year Clinical Outcomes of the REVELATION Study: Sustained Safety and Feasibility of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction

01/03/2022

Sander R. Niehe , MD;

René J. Van Der Schaaf , MD, PhD;

Jean-Paul R. Herrman , MD, PhD;

Nicola S. Vos , MD;

Mark S. Patterson , MBBS, PhD, MD, MRCP;

Ton Slagboom , MD;

Giovanni Amoroso , MD, PhD;

Maarten A. Vink , MD, PhD;

The randomized REVELATION trial showed that in the setting of STEMI, a drug-coated balloon strategy was non-inferior to a drug-eluting stent strategy in terms of fractional flow reserve assessed at 9 months. The aim of the present study is to...

The randomized REVELATION trial...

01/03/2022

Journal of Invasive Cardiology